| Literature DB >> 28545161 |
Ana I Coelho1,2, Jörgen Bierau2, Martijn Lindhout2, Jelle Achten2, Boris W Kramer3, M Estela Rubio-Gozalbo1,2.
Abstract
Classic galactosemia results from deficient activity of galactose-1-phosphate uridylyltransferase (GALT), a key enzyme of galactose metabolism. Despite early diagnosis and early postnatal therapeutic intervention, patients still develop neurologic and fertility impairments. Prenatal developmental toxicity has been hypothesized as a determinant factor of disease. In order to shed light on the importance of prenatal GALT activity, several studies have examined GALT activity throughout development. GALT was shown to increase with gestational age in 7-28 weeks human fetuses; later stages were not investigated. Prenatal studies in animals focused exclusively on brain and hepatic GALT activity. In this study, we aim to examine GALT specific activity in late prenatal and adult stages, using a sheep model. Galactosemia acute target-organs-liver, small intestine and kidney-had the highest late prenatal activity, whereas the chronic target-organs-brain and ovary-did not exhibit a noticeable pre- or postnatal different activity compared with nontarget organs. This is the first study on GALT specific activity in the late prenatal stage for a wide variety of organs. Our findings suggest that GALT activity cannot be the sole pathogenic factor accounting for galactosemia long-term complications, and that some organs/cells might have a greater susceptibility to galactose toxicity. Anat Rec, 300:1570-1575, 2017.Entities:
Keywords: GALT enzyme activity; chronic complications; classic galactosemia; developmental basis of disease; neonatal complications; prenatal toxicity; sheep model
Mesh:
Substances:
Year: 2017 PMID: 28545161 DOI: 10.1002/ar.23616
Source DB: PubMed Journal: Anat Rec (Hoboken) ISSN: 1932-8486 Impact factor: 2.064